Maillard Reaction inhibitor compositions
    5.
    发明授权
    Maillard Reaction inhibitor compositions 失效
    美拉德反应的抑制剂的组合物。

    公开(公告)号:EP0474874B1

    公开(公告)日:1995-10-18

    申请号:EP91903819.0

    申请日:1991-02-08

    发明人: INOUE, Jun

    IPC分类号: A61K31/195

    CPC分类号: A61K31/195

    摘要: A Maillard reaction inhibitor containing a substance represented by general formula (I), a pharmaceutically acceptable ester thereof, and a pharmaceutically acceptable salt of the substance or the ester, wherein X represents hydroxyl or nitro. It is used for treating or preventing various complications of diabetes, such as coronary artery disease, peripheral circulatory disturbance, cerebrovascular disease, neurosis, nephropathy, arteriosclerosis, arthrosclerosis, cataract and retinitis, and similar diseases caused by aging, such as atherosclerosis, coronary heart disease, cerebrovascular disease, senile cataract, and so forth.

    PHARMACEUTICAL CONTAINING PPAR AGONIST
    7.
    发明公开
    PHARMACEUTICAL CONTAINING PPAR AGONIST 有权
    药剂师ZUSAMMENSETZUNG MIT EINEM PPAR-DELTA AGONISTEN

    公开(公告)号:EP2151438A1

    公开(公告)日:2010-02-10

    申请号:EP08764395.3

    申请日:2008-05-20

    摘要: Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.
    A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.

    摘要翻译: 提供用于促进睑板腺上皮细胞或角膜上皮细胞增殖的药剂,以及眼部疾病如睑板腺功能障碍,干眼症等的治疗剂。 含有[3- [2- [4-异丙基-2-(4-三氟甲基)苯基-5-噻唑基]乙基] -5-甲基-1,2-苯并异恶唑-6-基]氧基乙酸[4- [3- [2-(4-三氟甲基)苯基-4-异丙基-5-噻唑基]丙酰基] -2-甲基苯氧基]乙酸或[4- [3- [2-(2-羟基-4-氯苯基) 5-异丙基-4-恶唑基〕丙酰基〕-2-甲基苯氧基〕乙酸或其药学上可接受的盐作为活性成分,用作促进睑板腺上皮细胞或角膜上皮细胞增殖的药剂,以及 诸如睑板腺功能障碍,干眼症等眼部疾病的治疗剂。

    PHARMACEUTICAL COMPRISING PPAR AGONIST
    9.
    发明公开
    PHARMACEUTICAL COMPRISING PPAR AGONIST 有权
    药品MITTEL MIT EITEM PPAR-AGONISTEN

    公开(公告)号:EP1964575A1

    公开(公告)日:2008-09-03

    申请号:EP06833405.1

    申请日:2006-11-27

    摘要: An object of the present invention is to provide an agent for promoting proliferation of a meibomian gland epithelial cell and a corneal epithelial cell, as well as provide an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye.
    There are provided an agent for promoting proliferation of a meibomian gland epithelial cell or a corneal epithelial cell, containing a PPARα or δ agonist as an active ingredient, as well as an agent for treating an ocular disease such as meibomian gland dysfunction or evaporative dry eye, containing a PPARα or δ agonist as an active ingredient.

    摘要翻译: 本发明的目的是提供一种用于促进睑板腺上皮细胞和角膜上皮细胞增殖的药剂,以及提供治疗诸如睑板腺功能障碍或蒸发干眼症的眼部疾病的药剂。 提供了用于促进睑板腺上皮细胞或角膜上皮细胞的增殖的试剂,其含有PPAR±或'激动剂作为活性成分,以及用于治疗眼部疾病如睑板腺功能障碍或蒸发干燥的药剂 眼睛,含有PPAR±或'激动剂作为活性成分。